Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Patent
1996-11-07
1998-10-20
Jordan, Kimberly
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
514178, 514814, 514866, 514909, A61K 3156
Patent
active
058246681
ABSTRACT:
Disclosed are compositions including at least one 5.beta. steroid and an amorphous cyclodextrin. Also disclosed are methods for treating a condition such as obesity, diabetes syndrome, diabetes-associated hypercorticoidism, combinations thereof, and anemic disorders by administering to a mammal in need of such treatment a composition including an obesity-, diabetes-, or anemia antagonistic amount of at least one 5.beta. steroid and an amorphous cyclodextrin. Furthermore, disclosed are methods for treating a subject for a condition that responds to treatment with DHEA by administering to the subject at least one 5.beta. steroid and DHEA in an amount that minimizes the contribution of the DHEA to the production of testosterone and estradiol while maximizing an amount of .alpha.ET and .beta.ET circulating in the subject's blood from an initial dose administered to the subject.
REFERENCES:
patent: 4024223 (1977-05-01), Noda et al.
patent: 4228160 (1980-10-01), Szejtli et al.
patent: 4232009 (1980-11-01), Hayashi et al.
patent: 4351846 (1982-09-01), Matsumoto et al.
patent: 4352793 (1982-10-01), Yamahira et al.
patent: 4383992 (1983-05-01), Lipari
patent: 4407795 (1983-10-01), Nicolau et al.
patent: 4424209 (1984-01-01), Tuttle
patent: 4425336 (1984-01-01), Tuttle
patent: 4438106 (1984-03-01), Wagu et al.
patent: 4474811 (1984-10-01), Masuda et al.
patent: 4478995 (1984-10-01), Shinoda et al.
patent: 4479944 (1984-10-01), Hayashi et al.
patent: 4479966 (1984-10-01), Hayashi et al.
patent: 4497803 (1985-02-01), Harada et al.
patent: 4499085 (1985-02-01), Masuda
patent: 4507289 (1985-03-01), Coleman et al.
patent: 4518595 (1985-05-01), Coleman et al.
patent: 4524068 (1985-06-01), Szejtli et al.
patent: 4555504 (1985-11-01), Jones
patent: 4565807 (1986-01-01), Uekama et al.
patent: 4575548 (1986-03-01), Ueda et al.
patent: 4596795 (1986-06-01), Pitha
patent: 4598070 (1986-07-01), Ohwaki et al.
patent: 4603123 (1986-07-01), Chiesi et al.
patent: 4608366 (1986-08-01), Hasegawa et al.
patent: 4623641 (1986-11-01), Szejtli et al.
patent: 4659696 (1987-04-01), Hirai et al.
patent: 4663316 (1987-05-01), Ninger et al.
patent: 4666898 (1987-05-01), Coleman et al.
patent: 4675395 (1987-06-01), Fukazawa et al.
patent: 4727064 (1988-02-01), Pitha
patent: 4728509 (1988-03-01), Shimizu et al.
patent: 4728510 (1988-03-01), Shibanai et al.
patent: 4751095 (1988-06-01), Karl et al.
patent: 4871726 (1989-10-01), Applezweig et al.
patent: 4920115 (1990-04-01), Nestler et al.
patent: 4983586 (1991-01-01), Bodor
patent: 5006517 (1991-04-01), Bradlow et al.
patent: 5024998 (1991-06-01), Bodor
Brewster, M. et al. "Preparation, Characterization, and Anesthetic Properties of 2-Hydroxypropyl-.beta.-cyclodextrin Complexes of Pregnanolone and Pregnenolone in Rat and Mouse", J. Pharm. Sciences, 84:10, 1154-1159 (Oct. 1995).
Shimada, et al., "Studies on Neurosteriods.I.Retention Behavior of Derivatized 17-Oxosteroids Using High-Performance Liquid Chromatography", J. Liquid Chromatography, 18:4, 712-723 (1995).
Yen et al., "Prevention of Obesity in A.sup.vy /a Mice by Dehydroepiandrosterone", Lipids, 12(5), 409 (1977).
Coleman, "Diabetes-Obesity Syndromes in Mice", Diabetes, 31 (Suppl. 1), 1 (1982).
Coleman et al., "Therapeutic Effects of Dehydroepiandrosterone Metabolites in Diabetes Mutant Mice", Endocrinology, 115, 239 (184).
Coleman, Antiobesity Effects of Etiocholanolones in Diabetes (db), Viable Yellow (A.sup.vy), and Normal Mice Endocrinology, 117, 2279 (1985).
Zumoff et al., "A Randomized Double-Blind Crossover Study of the Antiobesity Effects of Etiocholanedione", Obesity Research, 2, 13 (1994).
Gardner et al., "Androstane Therapy to Treat Aplastic Anaemia in Adults: An Uncontrolled Pilot Study", British Journal of Hematology, 65, 295 (1987).
Kappas et al., "The Pyrogenic Effect of Etiocholanolone (3.alpha.-Hydroxyetiocholane-17-One)", J. Clin. Endocr., 16, 948 (1956).
Kappas et al., "Studies on Pyrogenic Steroids in Man", Tans. Assn. Am. Phys., 72, 54 (1959).
Bradlow et al., "Some Aspects of the Dynamics of Oxidation-Reduction of Etiocholanolone-3-.sup.3 H-.sup.14 C in Man", J. Clin. Endocr., 27, 1203 (1967).
Bekers et al., "Stabilization of Mitomycins on Complexation With Cyclodextrins in Aqueous Acidic Media", Intl. J. of Pharmaceutics, 52, 239 (1989).
Bradlow H. Leon
Fineman Elliott L.
Rubinfeld Joseph
Vida Julius A.
Fineman Elliott L.
Jordan Kimberly
Supergen, Inc.
LandOfFree
Formulation for administration of steroid compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Formulation for administration of steroid compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Formulation for administration of steroid compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-244497